ChemoCentryx ContactSite Map
News & Events

Overview

Corporate Governance

Annual Reports

SEC Filings


Stock Information

Press Releases

Events & Presentations

contact Info

FAQs

Shareholder Tools

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.

Stock Chart
Stock price graph
     
Stock Quote
NASDAQ: CCXI
Price:
12.58
Change:
- 0.02
Day High:
12.82
Day Low:
12.29
Volume:
173,000
4:11 PM ET on Jun 18, 2013
Delayed at least 20 minutes.
Provided by eSignal.

View all »   RSSRecent News

Jun 5, 2013
ChemoCentryx to Present at Two Upcoming Healthcare Conferences and Ring Opening Bell at the NASDAQ Stock Market

May 28, 2013
ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein, MD, to Company's Board of Directors

May 21, 2013
ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor

View all »Events & Presentations

Jun 19, 2013 at 8:20 AM ET
Wells Fargo Securities 2013 Healthcare Conference

^ Return to Top